initial public offerings (IPOs) trading on American exchanges

Friday, September 13, 2013

Aratana Therapeutics (PETX) : 3-month performance

Sector: Healthcare > Industry: Veterinary Drugs

Aratana Therapeutics, Inc. is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe. The Company is developing several compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence, and licensed non-opioid local anesthetic for treating post-operative pain. The company is actively identifying additional programs to in-license from human health companies in order to expand its development pipeline of animal medicines.


1901 Olathe Blvd
United States 

Website links

Key stats and ratios

Q1 (Mar '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets--68.86%
Return on average equity--

No comments:

Post a Comment